<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of uncomplicated vulvovaginal candidiasis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of uncomplicated vulvovaginal candidiasis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of uncomplicated vulvovaginal candidiasis</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup> <colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug and trade name(s)</td> <td class="subtitle1">Requires a prescription in US</td> <td class="subtitle1">Preparation</td> <td class="subtitle1">Intravaginal* dose for adult</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Fluconazole oral administration<sup>¶</sup></td> </tr> <tr> <td class="indent1">Diflucan<sup>Δ</sup></td> <td>Yes</td> <td>150 mg oral tablet</td> <td>Single dose by mouth; patients with greater vulvovaginal involvement may require an additional dose of 150 mg given 72 hours after initial dose</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Clotrimazole</td> </tr> <tr> <td class="indent1">Gyne-Lotrimin<sup>Δ</sup></td> <td>No</td> <td>1% vaginal cream</td> <td>1 applicatorful (approximately 5 g) once daily at bedtime for seven days</td> </tr> <tr> <td class="indent1">Gyne-Lotrimin 3<sup>Δ</sup></td> <td>No</td> <td>2% vaginal cream</td> <td>1 applicatorful (approximately 5 g) once daily at bedtime for three days</td> </tr> <tr> <td class="indent1">Gyne-Lotrimin<sup>◊</sup></td> <td>Not applicable (not available in US)</td> <td> <p>100 mg vaginal tablet<sup>◊</sup></p> <p>200 mg vaginal tablet<sup>◊</sup></p> 500 mg vaginal tablet<sup>◊</sup></td> <td> <p>Insert one 100 mg vaginal tablet once daily for seven days; or</p> <p>One 200 mg tablet once daily for three days; or</p> One 500 mg tablet as a single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Miconazole</td> </tr> <tr> <td class="indent1">Monistat 7<sup>Δ</sup></td> <td>No</td> <td>2% vaginal cream (combination kit may include 2% miconazole cream for external use)</td> <td>1 applicatorful (approximately 5 g) once daily at bedtime for seven days</td> </tr> <tr> <td class="indent1">Monistat 3<sup>Δ</sup></td> <td>No</td> <td>4% vaginal cream</td> <td>1 applicatorful (approximately 5 g) once daily at bedtime for three days</td> </tr> <tr> <td class="indent1">Monistat 7<sup>Δ</sup></td> <td>No</td> <td>100 mg vaginal suppository</td> <td>1 suppository once daily at bedtime for seven days</td> </tr> <tr> <td class="indent1">Monistat 3<sup>Δ</sup>, Vagistat-3<sup>Δ</sup></td> <td> <p>No (combination kit)</p> Yes (generic suppository)</td> <td>200 mg vaginal suppository (combination kit may include 2% miconazole cream for external use)</td> <td>1 suppository once daily at bedtime for three days</td> </tr> <tr> <td class="indent1">Monistat 1<sup>Δ</sup></td> <td>No</td> <td>1200 mg vaginal suppository (combination kit may include 2% miconazole cream for external use)</td> <td>1 suppository for one day as a single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Nystatin<sup>§</sup></td> </tr> <tr> <td class="indent1">Nystatin vaginal<sup>◊</sup> (former US brand Mycostatin)</td> <td>Commercial vaginal tablet not available in US; vaginal suppositories can be prepared by a licensed compounding pharmacy (prescription required)</td> <td>100,000 unit vaginal tablet or suppository</td> <td>Insert 1 vaginal tablet or suppository once daily for 7 days</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Terconazole<sup>¥</sup></td> </tr> <tr> <td class="indent1">Generic only (former US brands Terazole 7, Zazole)<sup>Δ</sup></td> <td>Yes</td> <td>0.4% vaginal cream</td> <td>1 applicatorful (approximately 5 g) once daily at bedtime for seven days</td> </tr> <tr> <td class="indent1">Generic only (former US brands Terazole 3, Zazole)<sup>Δ</sup></td> <td>Yes</td> <td>0.8% vaginal cream</td> <td>1 applicatorful (approximately 5 g) once daily at bedtime for three days</td> </tr> <tr> <td class="indent1">Generic only (former US brands Terazole 3, Zazole)<sup>Δ</sup></td> <td>Yes</td> <td>80 mg vaginal suppository</td> <td>1 suppository once daily at bedtime for three days</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Tioconazole</td> </tr> <tr> <td class="indent1">Vagistat-1, Monistat 1-Day<sup>Δ</sup></td> <td>No</td> <td>6.5% vaginal ointment</td> <td>1 applicatorful (approximately 5 g) at bedtime as a single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Butoconazole</td> </tr> <tr> <td class="indent1">Gynazole-1</td> <td>Yes</td> <td>2% vaginal cream</td> <td>1 applicatorful (approximately 5 g) as a single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Ibrexafungerp</td> </tr> <tr> <td class="indent1">Brexafemme</td> <td>Yes</td> <td>150 mg oral tablet</td> <td> <p>Two 150 mg tablets (ie, 300 mg) by mouth twice a day for one day (4 tablets total).</p> <p>Limit use to <strong>non</strong>-pregnant patients who prefer oral dosing but cannot use oral fluconazole (eg, due to intolerance, allergy, or <em>Candida</em> infection resistant to fluconazole).</p> Dose reduction required if taken with strong CYP3A inhibitors.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Boric acid</td> </tr> <tr> <td class="indent1">AZO Boric acid, others<sup>‡</sup></td> <td>No</td> <td>600 mg vaginal suppository</td> <td> <p>1 suppository once daily at bedtime for 7 days.</p> Limit use to patients who are allergic to fluconazole and do not have access to other topical agents (ie, azoles and nystatin)<sup>‡</sup>. <strong>Warning: boric acid may cause death if taken orally.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>There are no significant differences in efficacy among topical and systemic azoles (cure rates &gt;80% for uncomplicated vulvovaginal candidiasis [VVC]). Patients can generally expect improvement in 24 to 48 hours. Complete resolution may take one to two weeks. Criteria for determining whether infection is uncomplicated/sporadic and guidance on choice of therapy is provided in associated topic and separate algorithm for sporadic uncomplicated VVC.</li>
<li>Complicated or recurrent infections require different treatment choices and durations from those presented in this table; refer to separate topic and algorithm for recurrent or complicated VVC.</li>
</ul></div><div class="graphic_footnotes"><p>US: United States; VVC: vulvogaginal candidiasis.</p>
<p>* Except fluconazole and ibrexafungerp, which are given orally.</p>
<p>¶ Itraconazole is another oral antifungal that appears to be effective<sup>[1]</sup>.</p>
<p>Δ Generic equivalent preparation(s) are available in US.</p>
<p>◊ Not commercially available in US.</p>
<p>§ Cure rate with nystatin is 70 to 80%.</p>
<p>¥ Rare cases of anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy.</p>
    
    ‡ Boric acid efficacy established with compounded intravaginal capsules which are not commercially available.</div><div class="graphic_reference">Reference:
    <ol>
<li>Pitsouni E, Iavazzo C, Falagas ME. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2008; 198:153.</li>
</ol>
<p class="extra_spacing_top">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</p></div><div id="graphicVersion">Graphic 71686 Version 28.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
